Gelteq Ltd. operates as a biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 7 full-time employees. The company went IPO on 2024-10-29. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
최신 재무제표(Form-10K)에 따르면, Gelteq Ltd의 총 자산은 $0이며, 순손실입니다.
GELS의 주요 재무 비율은 무엇인가요?
Gelteq Ltd의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Gelteq Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Gelteq Ltd 주요 수익원은 Gel Based Delivery System for Humans and Animals이며, 최신 수익 발표에서 수익은 107,276입니다. 지역별로는 United States이 Gelteq Ltd의 주요 시장이며, 수익은 81,371입니다.